{"entity":{"id":"excalipoint-therapeutics","kind":"company","name":"Excalipoint Therapeutics","aka":["Excalipoint Therapeutics Inc."],"tldr":"Excalipoint Therapeutics develops three-armed antibodies that attach immune T cells to solid-tumour cells and switch them on more fully. Its lead medicine, aimed at the protein DLL3 on small cell lung cancer and neuroendocrine tumours, is in an early clinical trial.","summary":"Excalipoint Therapeutics, a Shanghai company working from the Roche Accelerator building, launched publicly on 18 March 2026 with USD 68.7 million in financing: a USD 41 million seed round completed in 2025 and a USD 27.7 million extension. Its backers include HSG, Lilly Asia Ventures and Eisai's venture arm. The lead EXP011 is a trispecific T cell engager against DLL3 plus two immune cell targets, in phase 1/2 for small cell lung cancer and neuroendocrine tumours. A second trispecific, EXP012, adds CDH17 as the tumour target. Both were licensed from Lepu Biopharma for USD 10 million upfront. Chief executive Lei Fang was previously a vice president at Lepu.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.excalipoint.com/"},{"label":"BioPharma Dive: Excalipoint banks USD 69M","url":"https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/"}],"tags":[],"related":[],"cancers":["sclc","neuroendocrine"],"sections":["immunotherapy"],"technologies":["t-cell-engager","trispecific-antibodies"],"targets":["dll3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website (read 29 October 2026) confirms only that it is a clinical-stage T-cell engager company with EXCOPIA, EXiShield and EXPROMA platforms and that EXP011 is in phase 1/2 for solid tumours; the financing, the Lepu licence and the targets come from BioPharma Dive (18 March 2026). The two immune cell targets of EXP011 were not confirmed on a page read for this record, so they are not linked. Founding in August 2025 is reported by BioCentury but not stated by the company, so founded is left blank."],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.excalipoint.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2025,"amountUsd":41000000,"source":"https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/"},{"round":"Seed extension","year":2026,"amountUsd":27700000,"source":"https://www.biopharmadive.com/news/excalipoint-biotech-startup-china-t-cell-engagers/814829/","note":"Total of USD 68.7 million announced at launch in March 2026"}]},"route":"/companies/excalipoint-therapeutics/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/"}],"target":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/"}]}}